Australia markets close in 5 hours 37 minutes

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

NSE - NSE Real-time price. Currency in INR
Add to watchlist
1,495.10-44.20 (-2.87%)
At close: 03:29PM IST
Currency in INR

Valuation measures4

Market cap (intra-day) 3.69T
Enterprise value 3.53T
Trailing P/E 38.58
Forward P/E 26.67
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.74
Price/book (mrq)5.80
Enterprise value/revenue 7.38
Enterprise value/EBITDA 25.40

Trading information

Stock price history

Beta (5Y monthly) 0.53
52-week change 362.89%
S&P500 52-week change 327.84%
52-week high 31,638.85
52-week low 3937.00
50-day moving average 31,552.35
200-day moving average 31,339.97

Share statistics

Avg vol (3-month) 32.51M
Avg vol (10-day) 31.82M
Shares outstanding 52.4B
Implied shares outstanding 62.41B
Float 81.06B
% held by insiders 154.69%
% held by institutions 127.02%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 412.5
Forward annual dividend yield 40.81%
Trailing annual dividend rate 313.50
Trailing annual dividend yield 30.88%
5-year average dividend yield 40.93
Payout ratio 431.33%
Dividend date 3N/A
Ex-dividend date 409 Feb 2024
Last split factor 22:1
Last split date 329 July 2013

Financial highlights

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 19.75%
Operating margin (ttm)20.37%

Management effectiveness

Return on assets (ttm)7.84%
Return on equity (ttm)15.20%

Income statement

Revenue (ttm)484.97B
Revenue per share (ttm)202.06
Quarterly revenue growth (yoy)9.60%
Gross profit (ttm)N/A
EBITDA 129.87B
Net income avi to common (ttm)95.76B
Diluted EPS (ttm)39.87
Quarterly earnings growth (yoy)33.80%

Balance sheet

Total cash (mrq)191.05B
Total cash per share (mrq)79.89
Total debt (mrq)32.74B
Total debt/equity (mrq)4.88%
Current ratio (mrq)2.56
Book value per share (mrq)266.22

Cash flow statement

Operating cash flow (ttm)121.35B
Levered free cash flow (ttm)75.42B